250 related articles for article (PubMed ID: 7674319)
1. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
2. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas.
Zheng J; Wan M; Zweizig S; Velicescu M; Yu MC; Dubeau L
Cancer Res; 1993 Sep; 53(18):4138-42. PubMed ID: 8364906
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
[TBL] [Abstract][Full Text] [Related]
4. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
5. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical study of p53 protein in ovarian mucinous neoplasms.
Teh M; Lee YS
Pathology; 1996 Aug; 28(3):217-9. PubMed ID: 8912347
[TBL] [Abstract][Full Text] [Related]
7. Potential role of the inactivated X chromosome in ovarian epithelial tumor development.
Cheng PC; Gosewehr JA; Kim TM; Velicescu M; Wan M; Zheng J; Felix JC; Cofer KF; Luo P; Biela BH; Godorov G; Dubeau L
J Natl Cancer Inst; 1996 Apr; 88(8):510-8. PubMed ID: 8606379
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity in benign and malignant epithelial ovarian tumors.
Wan M; Li WZ; Duggan BD; Felix JC; Zhao Y; Dubeau L
J Natl Cancer Inst; 1997 Mar; 89(6):437-41. PubMed ID: 9091645
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
10. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.
McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L
Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry.
Kappes S; Milde-Langosch K; Kressin P; Passlack B; Dockhorn-Dworniczak B; Röhlke P; Löning T
Int J Cancer; 1995 Feb; 64(1):52-9. PubMed ID: 7665249
[TBL] [Abstract][Full Text] [Related]
12. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
Werness BA; DiCioccio RA; Piver MS
Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients.
Devaney K; Goodman ZD; Ishak KG
Am J Surg Pathol; 1994 Nov; 18(11):1078-91. PubMed ID: 7943529
[TBL] [Abstract][Full Text] [Related]
14. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
17. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
18. p63 expression in epithelial ovarian tumors.
Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
[TBL] [Abstract][Full Text] [Related]
19. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
20. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis.
Cheng P; Schmutte C; Cofer KF; Felix JC; Yu MC; Dubeau L
Br J Cancer; 1997; 75(3):396-402. PubMed ID: 9020485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
